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Abstract
Purpose This study aimed to investigate the prevalence of sleeping problems in prostate cancer survivors and to explore the role
of predisposing, precipitating and perpetuating factors in this process.
Methods Using a cross-sectional design, 3348 prostate cancer survivors between 2 and 18 years post diagnosis reported expe-
riences of insomnia using the QLQC30, along with their sociodemographic characteristics, health status and treatment(s)
received. The EQ5D-5L and QLQPR25 assessed survivors’ overall and prostate cancer–specific health-related quality of life.
A hierarchical multiple regression analysis was constructed with three blocks: (1) predisposing (e.g. demographics at diagnosis),
(2) precipitating (e.g. disease extent, treatment) and (3) perpetuating factors (e.g. side effects).
Results Nineteen percent of survivors reported significant problems sleeping. The final model accounted for 31% of the variance
in insomnia scores (p < .001). In order of magnitude, associates of sleep disturbance were urinary symptoms (β = 0.22; p < .001),
experiencing symptoms of depression/anxiety (β = 0.18; p < .001), hormone treatment–related symptoms (β = 0.12; p = .001),
pain (β = 0.10; p < .001) and bowel symptoms (β = 0.06; p = .005). Having a lower education and more comorbidities at diag-
nosis also predicted sleep problems.
Conclusion Results suggest that it is the ongoing adverse effects of prostate cancer and its treatment (e.g. urinary symptoms) that
put survivors most at risk of sleep problems. Strong associations with symptoms of depression/anxiety were also observed.
Findings highlight the need for health care practitioners to treat and manage adverse effects of prostate cancer treatment in order
to mitigate sleep disturbance in survivors.
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Introduction
The diagnosis and treatment of prostate cancer is associated
with a wide range of adverse effects, many of which can have
a detrimental impact on the quality of life of survivors [1–3].
Most research to date has concentrated on the specific physi-
cal adverse effects of the disease and its treatment (e.g. erectile
dysfunction, urinary incontinence and bowel problems), with
less work focusing on more general symptoms such as insom-
nia or sleep disturbance [4]. Nevertheless, insomnia has been
shown to be a common problem among survivors of many
types of cancer [5–7], including those with prostate cancer [6,
8, 9]. The negative effects of sleep disturbance have been well
documented, with those suffering from insomnia at a much
higher risk of a range of problems. However, while somework
has begun to shed light on the potential factors that put survi-
vors at risk of sleep difficulties, there is still a dearth of knowl-
edge in terms of how various factors combine to exacerbate
these problems.
Along with fatigue, sleep disturbance is the most common-
ly reported symptom in prostate cancer survivors [1, 8], al-
though estimates of the prevalence of sleep difficulties vary
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significantly across studies, ranging from as low as 8% to as
high as 53% of survivors [4]. Beyond prostate cancer, as many
as 74% of patients with advanced cancer can be classified as
Bpoor sleepers^ [10]. The lack of agreement here is potentially
due to the many different ways in which sleep problems can
be defined and measured. While the general consensus is that
insomnia involves a persistent difficulty in initiating and/or
maintaining sleep [11], this term is typically used in the con-
text of a clinical diagnosis so may not present a complete
picture of the range of sleep disturbances that may be experi-
enced by cancer survivors.
In prostate cancer, a likely influence on sleep quality is the
particular treatment undertaken by patients. A number of stud-
ies have suggested that undergoing any form of active treat-
ment puts survivors at greater risk of sleep problems [12],
although some treatments have a more detrimental effect than
others. In particular, androgen deprivation therapy (ADT) has
been associated with greater levels of sleep disturbances [13].
This is most likely due to the side effects of ADT, with some
work showing that sleep problems in this group are mediated
by associated symptoms, such as night sweats and nocturia
[12–15]. Such side effects have also been shown to lead to
insomnia in breast cancer survivors [12]. However, other com-
mon side effects associated with prostate cancer treatment,
such as urinary problems, can also lead to night time waking
and potentially exacerbate sleep problems further [13].
It could of course be the case that prostate cancer survivors
already had a risk of developing symptoms of insomnia prior
to treatment, or indeed may have had problems with sleeping
that pre-dated their diagnosis. For example, one study [9] re-
ported that half of prostate cancer survivors who met the
criteria for chronic insomnia syndrome (specifically defined
as a difficulty initiating or maintaining sleep for at least three
nights a week, leading to significant daytime impairment) re-
ported sleep difficulties prior to their cancer diagnosis. Indeed,
in the general population, certain risk factors for insomnia
have been identified, including, for example, younger age
[16]. These factors may influence the likelihood of survivors
experiencing sleep difficulties, irrespective of disease extent
and treatment undertaken.
Reflecting the diverse elements associated with sleep dis-
turbance, an influential theory of insomnia has proposed that
sleep difficulties are caused by a combination of (1) predis-
posing, (2) precipitating and (3) perpetuating factors [17].
This theory, often referred to as the Bthree Ps^model, has also
been adapted to explain insomnia in cancer survivors [18–21].
Specifically, predisposing factors have been considered to be
those that put individuals at risk of sleep problems prior to
diagnosis (e.g. sociodemographic characteristics at diagnosis),
precipitating factors are those that trigger sleep difficulties
upon diagnosis and treatment, while perpetuating factors have
been viewed as those factors that maintain sleep disturbances
post diagnosis.
We argue that a similar approach can be applied to un-
derstanding sleep disturbance in prostate cancer; however,
our conceptualisation of the three Ps model deviates slight-
ly from previous work. In other studies, the adverse effects
resulting from cancer treatment have been classified as
precipitating factors [18], while perpetuating factors have
been viewed as the actions that people take in order to
compensate for, or cope with, sleepiness (for example, caf-
feine consumption or time spent in bed). We propose, how-
ever, that the adverse effects of cancer and treatment are
better viewed as perpetuating factors, as these relate to the
ongoing, often chronic, experiences of survivors that ex-
tend beyond the initial diagnosis and treatment of cancer.
These could include the aforementioned urinary problems
and night sweats, as well as a range of other physical ef-
fects of cancer and its treatment.
Sleep problems may also be perpetuated by psycholog-
ical factors, such as symptoms of depression or anxiety. It
is known that such symptoms co-occur with sleep distur-
bance in cancer [18]; however, the exact nature of the re-
lationship between insomnia and depression/anxiety is un-
clear. Large-scale longitudinal studies suggest a bidirec-
tional relationship between the two [22] meaning that the
experience of each disorder predicts the later onset of the
other. Some work also suggests that an increase in anxiety
levels in cancer survivors can lead to an increased risk of
insomnia incidence [20, 23]. It is possible that experienc-
ing high levels of anxiety may perpetuate ongoing sleep
difficulties, particularly given that prostate cancer survi-
vors are known to experience fears of recurrence [24].
We hence conceptualise psychological variables here as
potentially perpetuating sleep disturbance.
In sum, a greater understanding of the factors that put pros-
tate cancer survivors at risk of sleep problems is merited. In
this study, we aimed to systematically explore how the previ-
ously defined predisposing, precipitating and perpetuating
factors are associated with sleep disturbance across different
phases of prostate cancer survivorship.
Methods
Sample and design
This study formed part of the PiCTure (Prostate Cancer
Treatment, your experience) project which was designed to in-
vestigate the experiences of a representative sample of prostate
cancer survivors in the Republic of Ireland (RoI) and Northern
Ireland (NI) [25]. Survivors were identified from two population-
based cancer registries, and a countrywide stratified sample of
12,322 men was identified (see supplementary figure for an
overview of sample recruitment). Inclusion criteria included be-
ing at least 2 years post diagnosis, being over the age of 18 and
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not suffering from any form of cognitive impairment that would
interfere with study participation [25]. This was determined by
health care professionals and was included to ensure that the
respondents would be in a position to give fully informed con-
sent. Following screening for eligibility by health care profes-
sionals (general practitioners in the RoI and urology clinical
nurses in NI), a total of 6559 survivors were invited to complete
a postal questionnaire between April and September 2012. In
addition to a cover letter, a consent form was included which
recipients were asked to sign and return alongside the question-
naire in a prepaid envelope. Non-respondents received two writ-
ten reminders approximately 2 weeks apart. The study was eth-
ically approved by the Irish College of General Practitioners and
from each of the five NI Trusts. Written informed consent was
obtained from all participants included in the study.
Instruments
Sleep disturbance
Survivors completed the EORTC QLQC30 (European
Organisation for Research and Treatment of Cancer Quality of
Life Questionnaire) which is a widely used, valid and reliable
measure of health-related quality of life in cancer survivors [26].
In addition to giving rise to five functional scales and a global
health score, this measure includes nine symptom scales, one of
which pertains to insomnia which constituted the outcome mea-
sure for the current study. To measure the extent of sleep prob-
lems, survivors were asked to rate whether they had experienced
trouble sleeping during the past week on a four-point scale (Bnot
at all,^ Ba little,^ Bquite a bit,^ or Bvery much^). Responses were
standardised as recommended [26] to give a score of 0–100, with
higher scores associated with greater levels of sleep disturbance.
Predisposing factors
Sociodemographic variables and health status at diagnosis
were classified as predisposing factors. Survivors were asked
to indicate their date of birth (which was used to calculate their
age at diagnosis) along with their marital status at diagnosis,
education level at diagnosis, employment status at diagnosis
and whether they had any children under the age of 16 at
diagnosis. Survivors were also asked whether they had any
additional health problems at diagnosis including, for exam-
ple, heart disease, diabetes, high blood pressure, diverticular
disease and/or other health problems. A total comorbidity
score was computed reflecting to the total number of health
conditions reported by respondents.
Precipitating factors
Precipitating factors were considered to be those relating to
cancer diagnosis and treatment. Survivors were classified by
disease extent at the time of diagnosis based on clinical stage
and Gleason Grade (GG). This information was obtained from
the National Cancer Registry Ireland (NCRI) and the Northern
Ireland Cancer Registry records. Following previous guide-
lines [27], survivors with stage I/II disease and a GG of 2–7
at diagnosis were classified as having localised disease,
whereas those with stage III/IV disease and any GG were
classified as having locally advancing/advanced disease.
Survivors with any other combinations of stage and GG as
well as those missing either a stage or grade classification
and therefore could not be clearly identified as having either
localised or advanced disease were included in a third catego-
ry (Bother^). Time since diagnosis was also recorded.
In addition, survivors indicated through self-report whether
they had received any of the following treatments for their
cancer: radical prostatectomy (RP), external beam radiation
therapy (EBBT), brachytherapy (BT), watchful waiting
(WW) and/or androgen deprivation therapy (ADT). In relation
to ADT, survivors also indicated whether this was a treatment
they had undergone previously or were undergoing currently.
Perpetuating factors
Perpetuating factors were considered to be any ongoing effects of
prostate cancer diagnosis and treatment and other indicators of
quality of life. These were assessed using two scales. Firstly,
survivors completed the QLQPR25 (Quality of Life
Questionnaire-Prostate 25) which measures prostate cancer–
specific symptoms [28]. Here, survivors indicated the extent to
which they encountered problems in urinary (seven items) and
bowel functions (four items), and other possible treatment-related
symptoms (six items) such as hot flushes, swelling and/or fluctu-
ations in weight. There were also specific questions relating to
those who wore an incontinence aid and those who had engaged
in sexual activity in the last 4 weeks; however, for the purposes of
this study, these subscales were not included in the analysis as
such symptoms were only applicable to a smaller subset of men
[29]. For all items, survivors indicated the extent that they had
experienced problems in the last week (or in the last 4 weeks for
some treatment-related symptoms, such as weight loss or gain) on
a scale of 1 (not at all) to 4 (very much). As recommended [28],
subscales were computed for each domain and scores
standardised from 0 to 100, with higher scores indicating greater
problems. The QLQPR25 has been previously demonstrated to
have acceptable psychometric properties and clinical validity [28].
Survivors also completed the EQ5D-5L which is a widely
used instrument for assessing generic health-related quality of
life developed by the EuroQoL group [30] and has been dem-
onstrated to have good reliability and validity in cancer patients
[31]. This required survivors to indicate if they had any prob-
lems in the following domains: mobility, self-care, usual activi-
ties, pain/discomfort and anxiety/depression. Items were rated
on a five-point scale ranging from 1 (no problems) to 5 (severe
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problems). Following an established procedure, responses were
categorised into a binomial variable representing whether survi-
vors exhibited any problems in each domain (0 = no problems;
1 = any problems, as indicated by a response of 2 or above).
Statistical analysis
Descriptive statistics were calculated including means, ranges
and standard deviations. No violations regarding assumptions
of linearity and homoscedasticity were observed. Examination
of correlations among independent variables revealed no
problems with multicollinearity. The outcome variable (in-
somnia subscale) was positively skewed, which is in line with
previous research using the QLQC30 [32, 33]. A number of
the predictor variables were also positively skewed including
all symptom subscales of the QLQPR25 and the total number
of comorbid conditions experienced. Linear regressionmodel-
ling can still be employed in predicting non-normally distrib-
uted data such as this, especially in cases where the sample
size is large and where the other assumptions are met [34]. A
hierarchical multiple regression model was hence constructed
to examine the associations between the three blocks of factors
and problems sleeping: (1) predisposing factors at diagnosis
(age, education, employment status, marital status, having
children living at home), (2) precipitating factors (disease ex-
tent at diagnosis, time since diagnosis and treatment, specifi-
cally having undergone RP, ERBT and ADT, either current or
previous treatment) and (3) perpetuating factors (three symp-
tom scales of QLQPR25 and five subscales of EQ5D-5L).
Missing data were handled using the pairwise deletion meth-
od. Associations with sleep problems were assessed using
two-sided t tests and p values of < 0.05 considered significant.
Results
Descriptive statistics
Following questionnaire dispatch, 5% of respondents were
deemed ineligible (see supplementary figure). After removing
these, a total of 3348 survivors were included in the study
(adjusted response rate = 54%). Analysis of the available infor-
mation from registry records revealed that survivors who were
less than 60 years old at diagnosis were more likely to respond
than those above the age of 60. No difference was observed in
time since diagnosis between responders and non-responders
meaning that each survival phase was well represented [25].
Table 1 displays descriptive statistics for the measures
used. At diagnosis, the majority of survivors were married
(83%), had completed at least primary education (67%), were
not in employment (51%) and had no children living at home
(78%).Most (56%) reported at least one other health problems
at diagnosis, with the most commonly reported problem being
Table 1 Descriptive statistics for sample
Categorical variables N. Percentage
Marital status
Married/cohabiting 2753 83%
Other 558 17%
Missing 37 1%
Total 3348 100%
Education
Primary 1187 36%
Secondary (high school) 1122 34%
Third level
(college/university or above)
899 27%
Missing 140 4%
Total 3348 100%
Employment status at diagnosis
Employed/self-employed 1455 44%
Other 1689 51%
Missing 204 6%
Total 3348 100%
Children living at home
Some children living at home 729 78%
No children living at home 2619 22%
Total 3348 100%
Disease extent at diagnosis
Localised 1449 43%
Locally advancing/advanced 502 15%
Other 1244 37%
Missing 153 5%
Total 3348 100%
Treatment*
RP 934 28%
ERBT 1718 51%
BT 183 6%
ADT past 912 27%
ADT current 657 20%
Watchful waiting 258 8%
Mobility (EQ5D)
Problems 1086 33%
No problems 2118 63%
Missing 144 4%
Total 3348 100%
Self-care (EQ5D)
Problems 419 13%
No problems 2798 84%
Missing 131 4%
Total 3348 100%
Usual activities (EQ5D)
Problems 1184 35%
No problems 2019 60%
Missing 145 4%
Total 3348 100%
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high blood pressure (30%), followed by heart disease (13%)
and diabetes (7%). Forty-three percent were classified as hav-
ing localised disease at diagnosis with 15% having advanced
disease. The most common treatment was ERBT (51%),
followed by ADT (47% had either currently or previously
received ADT) with 28% having undergone RP. Due to small
numbers undergoing BT (6%) and watchful waiting (8%),
these were not included in the final model.
Examination of prostate cancer–specific symptoms revealed
that most survivors did not report significant problems in the
three domains, although the most common of these were urinary
symptoms (M = 19.76; SD = 18.34), followed by treatment-
related symptoms (M= 10.62; SD= 12.80) and bowel symptoms
(M = 7.29; SD = 12.57). Results from all EQ5D-5L subscales
showed that the most commonly reported problem was pain
(37%), followed by problems with usual activities (35%), mobil-
ity (33%) and anxiety/depression (28%). Only a small proportion
of survivors (13%) reported problems with self-care.
When examining the QLQC30 insomnia subscale (see Fig. 1),
it can be seen that while the majority of the sample (54%)
reported having no trouble sleeping in the past week, almost
half reported some problems with 19% experiencing at least
Bquite a bit^ of trouble sleeping (M = 23.57; SD = 30.18).
Hierarchical regression analysis
Table 2 displays the results of the regression analysis. All three
blocks of factors were significant contributors to the model.
Firstly, when entering predisposing factors into block 1, 5.2%
of the variance in sleep problems were accounted for, with
significant associates at diagnosis being a greater number of
comorbid conditions (β = 0.17, p < .001), a lower level of ed-
ucation (β = − 0.09, p < .001), having no children at home
(β = − 0.05, p = .01), not being in employment (β = − 0.6,
p = .01) and being younger (β = − 0.05, p = .03). After enter-
ing the precipitating factors into block 2 of the model, a further
1.5% of variance in sleep problems was accounted for
(p < .001). At this step, significant associates were undergoing
ADTcurrently (β = 0.10, p = .001) and having more advanced
disease (β = 0.05, p = .02). Education, employment status, age
and comorbid conditions at diagnosis remained significant
associates of sleep problems at this stage; however, many of
these associations disappeared when entering the perpetuating
factors into block 3 of the model. This step contributed the
largest proportion of variance (24%) to levels of sleep distur-
bance (p < .001). Overall, the final model was significant and
explained a total of 31% of the variance in problems sleeping
(F(19, 2391) = 56.41; p < .001). In order of magnitude, the
strongest predictors were urinary symptoms (β = 0.22,
p < .001), problems with anxiety/depression (β = 0.18,
p < .001), treatment-related symptoms (β = 0.12, p < .001),
pain (β = 0.10, p < .001), bowel symptoms (β = 0.06,
p = .005), a lower level of education at diagnosis (β = − 0.05,
p = .007) and a greater number of comorbid conditions at di-
agnosis (β = 0.04, p = .033).
Discussion
Our results fit with a growing body of literature which sug-
gests that sleep disturbance is a common problem for prostate
cancer survivors [4, 8] In spite of having a reasonably high
quality of life, many survivors in our sample reported at least
some difficulties sleeping, which is consistent with previous
QLQC30 reference data for this group [35]. When compared
to population norms [32], the mean insomnia score we
Table 1 (continued)
Pain (EQ5D)
Problems 1236 37%
No problems 1962 59%
Missing 150 5%
Total 3348 100%
Anxiety/depression (EQ5D)
Problems 939 28%
No problems 2239 67%
Missing 170 5%
Total 3348 100%
Continuous variables Mean SD Range N
Survivor age 71.57 7.94 37–95 3319
Time since diagnosis (years) 6.42 3.57 2–17 3348
Number of comorbidities 0.86 0.97 0–7 3348
Urinary symptoms (QLQPR25) 19.76 18.34 0–100 2653
Bowel symptoms (QLQPR25) 7.29 12.57 0–100 2783
Treatment related symptoms
(QLQPR25)
10.62 12.80 0–100 2891
Sleep disturbance (Insomnia
subscale of QLQC30)
23.57 30.18 0–100 3174
RP radical prostatectomy, ERBT external beam radiotherapy, ADT an-
drogen deprivation therapy, QLQPR25 Quality of Life Questionnaire-
Prostate 25, QLQC30 Quality of Life Questionnaire-Cancer 30
*Note that treatment types are not mutually exclusive. Survivors could
have undergone more than one of the above
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%
55%
60%
Not all all A little Quite a bit Very much
Extent of problems sleeping over the past week
Fig. 1 Proportion of survivors reporting the extent of problems sleeping
(based on scores from the QLQC30 insomnia subscale)
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Table 2 Hierarchical multiple regression analysis
Variables β p t B SE 95% CI
Step 1: Predisposing factors
Age − 0.048* .033 − 2.139 − 0.181 0.085 − 0.347 − 0.015
Marital status [other = 0; married/cohabiting = 1] − 0.038 .056 − 1.914 − 3.084 1.611 − 6.244 0.076
Education level [higher = higher level of education] − 0.093*** .000 − 4.578 − 3.497 0.764 − 4.994 − 1.999
Children at home [no = 0; yes = 1] − 0.054** .007 − 2.689 − 3.979 1.480 − 6.881 − 1.077
Employment status [other = 0; employed = 1] − 0.056* .012 − 2.512 − 3.401 1.354 − 6.056 − 0.746
Comorbidity [higher = more pre-existing conditions] 0.173*** .000 8.564 5.377 0.628 4.146 6.609
R2 change = 0.052
Step 2: Precipitating factors
Age − 0.095*** .000 − 3.655 − 0.361 0.099 − 0.555 − 0.168
Marital status [other = 0; married/cohabiting = 1] − 0.039 .050 − 1.958 − 3.142 1.605 − 6.288 0.005
Education level [higher = higher level of education] − 0.090*** .000 − 4.445 − 3.381 0.761 − 4.873 − 1.889
Children at home [no = 0; yes = 1] − 0.048* .018 − 2.359 − 3.506 1.486 − 6.420 − 0.591
Employment status [other = 0; employed = 1] − 0.064** .006 − 2.766 − 3.859 1.395 − 6.595 − 1.124
Comorbidity [higher = more pre-existing conditions] 0.171*** .000 8.435 5.293 0.628 4.062 6.523
Time since diagnosis in years [higher = greater time] 0.042 .064 1.855 0.354 0.191 − 0.020 0.728
Disease extent [higher = more advanced] 0.051* .015 2.436 2.129 0.874 0.415 3.842
Treatment RP [no = 0; yes = 1] − 0.005 .856 − 0.181 − 0.352 1.947 − 4.169 3.465
Treatment ERBT [no = 0; yes = 1] − 0.012 .662 − 0.437 − 0.732 1.675 − 4.018 2.553
Treatment ADT previous 0.037 .137 1.489 2.457 1.650 − 0.780 5.693
Treatment ADT current 0.108*** .000 4.486 7.866 1.754 4.427 11.304
R2 change = 0.015
Step 3: Perpetuating factors
Age − 0.033 .144 − 1.461 − 0.126 0.086 − 0.296 0.043
Marital status [other = 0; married/cohabiting = 1] − 0.020 .235 − 1.188 − 1.647 1.386 − 4.365 1.072
Education level [higher = higher level of education] − 0.046** .009 − 2.630 − 1.735 0.660 − 3.029 − 0.441
Children at home [no = 0; yes = 1] − 0.020 .249 − 1.154 − 1.484 1.286 − 4.006 1.038
Employment status [other = 0; employed = 1] − 0.031 .120 − 1.554 − 1.878 1.208 − 4.246 0.491
Comorbidity [higher = more pre-existing conditions] 0.038* .038 2.081 1.168 0.561 0.067 2.269
Time since diagnosis in years [higher = greater time] 0.016 .415 .815 0.134 0.165 − 0.189 0.458
Disease extent [higher = more advanced] − 0.004 .837 − 0.205 − 0.156 0.760 − 1.647 1.335
Treatment RP [no = 0; yes = 1] − 0.014 .571 − 0.566 − 0.955 1.686 − 4.261 2.351
Treatment ERBT [no = 0; yes = 1] − 0.022 .368 − 0.900 − 1.311 1.457 − 4.168 1.546
Treatment ADT previous 0.013 .571 0.612 0.880 1.438 − 1.940 3.700
Treatment ADT current − 0.009 .676 − 0.418 − 0.667 1.596 − 3.797 2.463
Urinary symptoms [higher = worse] 0.218*** .000 10.188 0.359 0.035 0.290 0.428
Bowel symptoms [higher = worse] 0.056** .005 2.783 0.135 0.048 0.040 0.229
Treatment-related symptoms [higher = worse] 0.115*** .000 5.242 0.272 0.052 0.170 0.374
Mobility problem [no problems = 0; problems = 1] 0.029 .235 1.187 1.829 1.541 − 1.192 4.851
Self-care problems [no problems = 0; problems = 1] 0.018 .385 0.870 1.658 1.906 − 2.081 5.396
Problems with usual activities [no problems = 0; problems = 1] 0.044 .073 1.792 2.758 1.539 − 0.260 5.776
Pain [no problems = 0; problems = 1] 0.096*** .000 4.395 5.940 1.352 3.290 8.590
Anxiety/depression [no problems = 0; problems = 1] 0.181*** .000 9.155 11.980 1.309 9.414 14.546
R2 change = 0.24
Adjusted R2 = 0.31
RP radical prostatectomy, ERBT external beam radiotherapy, ADT androgen deprivation therapy
*p < .05; **p < .01; ***p < .001
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observed (M = 24; SD = 30) was higher than that of males in
the general population (M = 19; SD = 27). This implies that, in
spite of a large variability in experience, sleep disturbance is a
relatively common concern for prostate cancer survivors. We
have shown that, although a number of predisposing and pre-
cipitating factors may put survivors at risk of sleep difficulties,
the factors that we have classified as perpetuating factors,
specifically the ongoing side effects of prostate cancer and
its treatment, appear to have the strongest associations with
sleep disturbance.
Physical side effects of cancer
Prostate cancer diagnosis and treatment can give rise to a
range of physical adverse effects [1–3], and it is clear from
the results of our study that many of these effects are indepen-
dently related to the experience of sleep problems. The stron-
gest predictor here was urinary symptoms, which fits with a
number of studies and reviews in the area [4]. It is likely that
experiencing a more frequent need to urinate directly contrib-
utes to sleep problems owing to more night time waking [9].
Interestingly, although we initially found in step 2 of our
model that survivors undergoing current ADT experienced
higher levels of sleep disturbance, a result consistent with
other work in the area [12], any differences in sleep difficulties
between treatment groups disappeared when accounting for
such side effects. These results go beyond the findings of
previous studies to suggest that it is the adverse physical and
psychological effects of prostate cancer and its treatment, rath-
er than the treatment per se, that give rise to problems
sleeping. This highlights the importance of managing side
effects for all prostate cancer survivors, regardless of treatment
undergone. However, current interventions andmedications to
manage side effects are not widely employed [36].
Related to this, it is also notable that another strong predic-
tor of sleep difficulties was survivors’ reported levels of pain.
In the general population, longitudinal studies have similarly
documented that those with a higher level of bodily pain are
more likely to develop insomnia syndrome [23]. Other studies
suggest that those in chronic pain have an average Bsleep
debt^ of 42 min per week (defined as the difference between
self-reported sleep duration and the quantity of sleep respon-
dents felt they needed), in comparison to 14 min of sleep debt
for those who did not suffer from pain [37]. The fact that pain
predicted sleep problems in our sample, independently of oth-
er prostate-specific symptoms, illustrates the importance of
acknowledging this factor in the follow-up treatment of survi-
vors, including those who are up to 17 years post diagnosis.
Depression, anxiety and sleep disturbance
The second strongest associate with sleep difficulties in our
sample was the experience of depression and anxiety, a
finding consistent with a number of studies in the area. For
example, within prostate cancer, one study found that half of
survivors with clinically significant depression also exhibited
clinically significant insomnia [8]. More generally, other work
has demonstrated that mental health, as opposed to physical
health, better predicts chronic insomnia in a 7.5-year follow-
up [16]. Yet, while the relationship between insomnia and
mental health has been well established, there is some dis-
agreement as to whether higher levels of depression/anxiety
lead to insomnia, or vice versa. For example, in one
population-based longitudinal study of almost 25,000 partici-
pants [22], it was found that both depression and insomnia
significantly predicted the later onset of the other disorder.
Sleep difficulties can be viewed as both a symptom and a
correlate of various psychological disorders, and given the
cross-sectional nature of our study design, we cannot be sure
of the direction of this relationship in our sample. It is possible
that the co-occurrence of sleep disturbance and depression in
cancer survivors may stem from specific biologic processes
following treatment. In prostate cancer, it has also been argued
that sleep disturbances result from specific neurobiological
mechanisms which may in turn lead to a greater likelihood
of experiencing symptoms of depression [38].
Given that prostate cancer survivors are known to be at risk
of depression and anxiety [39, 40], it is reasonable to presume
that such factors in themselves could contribute to higher like-
lihood of night time waking. As with other cancers, prostate
cancer survivors can experience fears of recurrence, a type of
anxiety which can significantly impact on survivors’ quality
of life [41]. Some studies also suggest that cancer survivors
are at risk of developing post traumatic stress disorder (PTSD)
following diagnosis and treatment [42]. Given the well-
established relationships between PTSD and insomnia [43],
it seems likely that worsening mental health might lead to
difficulties sleeping in this group. However, it is also impor-
tant to acknowledge that insomnia often occurs independently
of anxiety or depression in prostate cancer [9]. Closer analysis
of our results revealed that of those survivors who did not
experience any problems with depression and/or anxiety,
10% still experienced significant sleep difficulties (defined
as at least Bquite a bit of trouble sleeping^). Conversely,
28% of those reporting problems with depression/anxiety ex-
perienced no sleep disturbance. This clearly illustrates that
poor mental health is not the only factor associated with sleep
difficulties.
Limitations
In considering our results, a number of limitations must be
acknowledged. Firstly, for the purposes of this study, we
conceptualised sleep disturbance simply as an individual’s
perceptions of whether they have any trouble sleeping.
There are other more objective ways of assessing sleep
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difficulties and of establishing clinically significantly levels of
insomnia [4], but this was beyond the scope of the current study.
We did not take into account whether survivors took any sleep-
inducting medications or indeed whether survivors had any
previously diagnosed sleep disorder, both of which may have
influenced the results. Also, older survivors may have been
underrepresented in our study based on analysis of non-re-
sponders, and this group may be more likely to experience
problems sleeping. Finally, the cross-sectional nature of the
design means that we must be cautious in interpreting the re-
sults, especially with respect to the temporal interpretation of
our findings. Nevertheless, this study has a number of key
strengths. Most notably, it involved a large population-based
sample of survivors, including long-term survivors, who had
undergone a range of treatments for prostate cancer, and there-
fore can give insight into the associates of sleep difficulties in a
range of individuals at different stages of survivorship.
Conclusions and implications
It is clear from the results of our study that many prostate cancer
survivors exhibit problems sleeping. An important consider-
ation for health care practitioners is therefore how best to treat
and manage symptoms of insomnia within this group. While
many US cancer centres screen survivors for sleep disorders,
very few conduct a thorough sleep evaluation [7]. Despite ev-
idence that cognitive-behavioural therapy is the most effective
treatment for insomnia [44], those that do attempt to treat in-
somnia in cancer tend to employ sleep hygiene and/or pharma-
cotherapy. Our findings suggest that, in treating sleep difficul-
ties, health care practitioners should work to effectively manage
both general and specific adverse effects of prostate cancer
treatment, in addition to behavioural modification techniques.
In conclusion, we have shown how sleep disturbance is
clearly associated with both the physical and psychological
symptoms associated with prostate cancer. This further
strengthens the need for practitioners to acknowledge and treat
the adverse effects of treatment in order to better enhance
survivor well-being.
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